CSL Ltd

CSL: XASX (AUS)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
m!!LOCK|p#!KLOCK|FB#y%$

CSL Earnings: CEO Change Is Welcome but Relatively Soft Plasma Performance to Postpone Recovery

CSL's interim 2026 underlying EBIT fell 3% on 5% lower plasma sales. Full-year guidance of mid-single-digit earnings growth was reaffirmed, and the Seqirus and Vifor divisions fared relatively well. But the soft plasma result and retirement of CEO Paul McKenzie sent shares down 11%.

Sponsor Center